Amid rising market fluctuations and shifting healthcare demands, Davipharm – a member of Adamed Group continued to consolidate its position throughout the year 2025 as one of Vietnam’s leading pharmaceutical manufacturers. The company pursued a long-term strategy anchored in high quality manufacturing, scientific engagement, public–private partnership and talent development, reflecting both national responsibility and international ambition.

Expanding scientific dialogue and global industry presence

In 2025, Davipharm deepened its engagement with Vietnam’s medical community through active participation in major scientific conferences organized by professional associations and hospitals nationwide. These events enabled the company to connect with thousands of HCPs across diverse therapeutic areas like andrology, cardiology, urology–nephrology, geriatrics, musculoskeletal disorders, including community pharmacy, hospital pharmacy and tobacco harm prevention.

Parallel to its domestic efforts, Davipharm strengthened its international visibility by participating in key pharmaceutical exhibitions such as CPHI Frankfurt, Pharmedi Vietnam, PharMed Cambodia, Medical Fair Thailand, etc. Through these platforms, the company exchanged technical expertise, monitored global industry trends and explored new cooperation opportunities across emerging and developed markets.

Photo: Davipharm at CPHI Frankfurt

A milestone was marked at the Polish MedTech Seminar in September 2025, organized by the Polish Investment and Trade Agency in collaboration with the Polish Embassy in Thailand within the activities of Medical Fair Thailand. Representing Adamed Group, Ms. Truong Quoc Huong – Sales and Marketing Director of Davipharm joined five other leading Polish medical technology companies to highlight Adamed’s expansion in Southeast Asia and Davipharm position’s as one of Poland’s largest direct investments in the region, underscoring its role as a strategic manufacturing and commercial hub for the group.

Advancing preventive healthcare and digital access

Adamed and Davipharm continued to align closely with Vietnam’s long-term public health priorities through sustained investment, collaboration and community-based initiatives. Central to this commitment is the “Chăm Sóc Sức Khỏe Việt” program, in 2025 provided free health screening for 6,500 Vietnamese citizens aged 35 and above at hospitals, healthcare facilities and social centers in Ho Chi Minh city and Vinh Long province.

Photo: Ms. Truong Quoc Huong – Sales and Marketing Director of Davipharm shared insights on public–private partnerships at the National Health Conference in May 2025.

Davipharm is the first and only local pharmaceutical company partnering with Vietnam Ministry of Health to implement a national program dedicated to non-communicable diseases (NCDs) prevention and early detection once a year. Since its launch in 2021, the initiative has screened and consulted nearly 30,000 people, reached approximately 10 million citizens through health communication activities and contributed to the training of nearly 3,000 doctors nationwide.

In the product and service field, Davipharm expanded its Eimler-10 portfolio for the treatment of type 2 diabetes with cardio-renal benefits, while accelerating its digital transformation agenda. Updated platforms such as https://chamsocsuckhoeviet.vn/ and zanus.vn enable patients to self-assess their health status, receive professional consultation via hotlines and order prescription medicines online through pharmacists, improving accessibility and continuity of care.

Investing in people and long-term growth

People development remained a core pillar of Davipharm’s strategy. In December 2025, the company collaborated with the University of Medicine and Pharmacy at Ho Chi Minh City and the University of Health Sciences – Vietnam National University HCMC to organize career talks for nearly 1,000 students. These sessions offered practical insights into pharmaceutical operations, sales and marketing, finance and manufacturing, alongside internship opportunities and factory tours, contributing to the development of a skilled workforce for the next growth phase of the industry.

Photo: Career Talk co-organized by Davipharm and University of Health Sciences – Vietnam National University HCMC

Earlier in the talent pipeline, the ADAMED SmartUP program with the Vietnamese editions since 2019, has supported more than 950 students from Vietnam–Poland High School, including sponsorship for selected students to participate in science summer camps in Poland, fostering early interest in science and innovation.

Davipharm’s consistent performance was recognized through multiple prestigious awards in 2025, including Top 10 Vietnam Golden Products, Top 10 Vietnam Leading Brands, high rankings in the Top 100 Vietnam Best Places to Work (#4 in Pharmaceutical/ Medical Equipment/ Healthcare Services and #38 among Top 100 Best Places to Work – Medium Enterprises), Top 50 Best Employer of Choice® by Vietnam Student (#6 in Medical/ Pharmaceutical/ Nursing majors), as well as the Happiness at Work™ Certification with an 81% Happiness Index exceeding the industry average.)

Currently, Davipharm supplies more than 300 pharmaceutical products across 12 therapeutic areas, with flagship brands such as Davyca, Dryches, Zapnex, Pizar and Zlatko (awarded Top 10 Vietnam Golden Products by Vietnam Intellectual Property Association) leading the market for many years, with good efficacy, affordable price, and the trust of physicians nationwide. Looking ahead, the company continues to strengthen compliance with international standards to expand exports to Asia, the Middle East and Eastern Europe, reinforcing the credibility of high-quality “Made in Vietnam” medicines.

Davipharm remains committed to sustained investment in research and development, factory expansion and manufacturing excellence, supporting Vietnam’s ambition to become a regional hub for high-value pharmaceutical production.

Source: Nhan Dan Newspaper